ID Biomedical goes to war
This article was originally published in Clinica
ID Biomedical is developing a battlefield gene detection system for the US government. ID, a Canadian company, has been working on a clinical system for detecting the DNA of infectious organisms for some time. It uses a technology known as the cycling probe reaction to amplify target DNA.
You may also be interested in...
The C-suite leaders schemed to falsely record shipments of unwanted products to distributors as sales so the company could meet revenue projections, the government charged.
Gallium has been approved as a diagnostic agent by the US agency to help early detection of prostate cancer spread in patients who qualify for treatment with surgery or radiation therapy.
A joint report by the US Government Accountability Office and the National Academy of Sciences slams the FDA for dawdling on final software as a medical device rules.